Kyowa Kirin Co., Ltd.

CRYSVITA® Now Publicly Reimbursed for the Treatment of Adults with XLH in Four Provinces and Federal Non-Insured Health Benefits Program

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis